Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

One-Time Intravitreal Injection of KVD001, a Plasma Kallikrein Inhibitor, in Patients with Central-Involved Diabetic Macular Edema and Reduced Vision: An Open-Label Phase 1B Study.

Sun JK, Maturi RK, Boyer DS, Wells JA, Gonzalez VH, Tansley R, Hernandez H, Maetzel A, Feener EP, Aiello LP.

Ophthalmol Retina. 2019 Dec;3(12):1107-1109. doi: 10.1016/j.oret.2019.07.006. Epub 2019 Jul 26. No abstract available.

PMID:
31810575
2.

Epidemiology of Bradykinin-mediated angioedema: a systematic investigation of epidemiological studies.

Aygören-Pürsün E, Magerl M, Maetzel A, Maurer M.

Orphanet J Rare Dis. 2018 May 4;13(1):73. doi: 10.1186/s13023-018-0815-5.

4.

The effect of walking on cardiorespiratory fitness in adults with knee osteoarthritis.

Larose J, King J, Brosseau L, Wells GA, Reid R, Maetzel A, Tugwell P, Huijbregts M, McCullough C, Loew L, Kenny GP.

Appl Physiol Nutr Metab. 2013 Aug;38(8):886-91. doi: 10.1139/apnm-2012-0487. Epub 2013 Mar 21.

PMID:
23855277
5.

Abatacept or infliximab for patients with rheumatoid arthritis and inadequate response to methotrexate: an Italian trial-based and real-life cost-consequence analysis.

Benucci M, Stam WB, Gilloteau I, Sennfält K, Leclerc A, Maetzel A, Lucioni C.

Clin Exp Rheumatol. 2013 Jul-Aug;31(4):575-83. Epub 2013 May 27.

PMID:
23711100
6.

The implementation of a community-based aerobic walking program for mild to moderate knee osteoarthritis: a knowledge translation randomized controlled trial: part II: clinical outcomes.

Brosseau L, Wells GA, Kenny GP, Reid R, Maetzel A, Tugwell P, Huijbregts M, McCullough C, De Angelis G, Chen L.

BMC Public Health. 2012 Dec 12;12:1073. doi: 10.1186/1471-2458-12-1073.

7.

The implementation of a community-based aerobic walking program for mild to moderate knee osteoarthritis (OA): a knowledge translation (KT) randomized controlled trial (RCT): Part I: The Uptake of the Ottawa Panel clinical practice guidelines (CPGs).

Brosseau L, Wells GA, Kenny GP, Reid R, Maetzel A, Tugwell P, Huijbregts M, McCullough C, De Angelis G, Chen L.

BMC Public Health. 2012 Oct 13;12:871. doi: 10.1186/1471-2458-12-871.

8.

Ottawa panel evidence-based clinical practice guidelines for aerobic walking programs in the management of osteoarthritis.

Loew L, Brosseau L, Wells GA, Tugwell P, Kenny GP, Reid R, Maetzel A, Huijbregts M, McCullough C, De Angelis G, Coyle D; Ottawa Panel.

Arch Phys Med Rehabil. 2012 Jul;93(7):1269-85. doi: 10.1016/j.apmr.2012.01.024. Epub 2012 Mar 12. Review.

PMID:
22421624
9.

Is a mass immunization program for pandemic (H1N1) 2009 good value for money? Evidence from the Canadian Experience.

Sander B, Bauch CT, Fisman D, Fowler RA, Kwong JC, Maetzel A, McGeer A, Raboud J, Scales DC, Gojovic MZ, Krahn M.

Vaccine. 2010 Aug 31;28(38):6210-20. doi: 10.1016/j.vaccine.2010.07.010. Epub 2010 Jul 17.

PMID:
20643091
10.

Economic appraisal of Ontario's Universal Influenza Immunization Program: a cost-utility analysis.

Sander B, Kwong JC, Bauch CT, Maetzel A, McGeer A, Raboud JM, Krahn M.

PLoS Med. 2010 Apr 6;7(4):e1000256. doi: 10.1371/journal.pmed.1000256.

11.

The OMERACT Initiative. Towards a reference approach to derive QALY for economic evaluations in rheumatology.

Boonen A, Maetzel A, Drummond M, Suarez-Almazor M, Harrison M, Welch V, Tugwell PS.

J Rheumatol. 2009 Sep;36(9):2045-9. doi: 10.3899/jrheum.090355.

PMID:
19738211
12.

A coordinator program in post-fracture osteoporosis management improves outcomes and saves costs.

Sander B, Elliot-Gibson V, Beaton DE, Bogoch ER, Maetzel A.

J Bone Joint Surg Am. 2008 Jun;90(6):1197-205. doi: 10.2106/JBJS.G.00980.

PMID:
18519311
13.

Rapid and sustained improvement in health-related quality of life and utility for 72 weeks in patients with ankylosing spondylitis receiving etanercept.

Boonen A, Patel V, Traina S, Chiou CF, Maetzel A, Tsuji W.

J Rheumatol. 2008 Apr;35(4):662-7. Epub 2008 Feb 15.

PMID:
18278836
14.

Direct costs of osteoporosis and hip fracture: an analysis for the Mexican healthcare system.

Clark P, Carlos F, Barrera C, Guzman J, Maetzel A, Lavielle P, Ramirez E, Robinson V, Rodriguez-Cabrera R, Tamayo J, Tugwell P.

Osteoporos Int. 2008 Mar;19(3):269-76. Epub 2007 Dec 5.

PMID:
18060586
15.

Considerations and preliminary proposals for defining a reference case for economic evaluations in ankylosing spondylitis.

Bansback N, Maetzel A, Drummond M, Anis A, Marra C, Conway P, Boers M, Tugwell P, Boonen A.

J Rheumatol. 2007 May;34(5):1178-83.

PMID:
17477483
16.

Cost effectiveness analysis of disease modifying antirheumatic drugs in rheumatoid arthritis.

Osiri M, Kamolratanakul P, Maetzel A, Tugwell P.

Rheumatol Int. 2007 Sep;27(11):1063-9. Epub 2007 Apr 14.

PMID:
17440729
17.

The economic burden of rheumatoid arthritis in a developing nation: results from a one-year prospective cohort study in Thailand.

Osiri M, Maetzel A, Tugwell P.

J Rheumatol. 2007 Jan;34(1):57-63. Epub 2006 Dec 15.

PMID:
17183621
18.

Primary therapist model for patients referred for rheumatoid arthritis rehabilitation: a cost-effectiveness analysis.

Li LC, Maetzel A, Davis AM, Lineker SC, Bombardier C, Coyte PC.

Arthritis Rheum. 2006 Jun 15;55(3):402-10.

19.
20.

Cost-effectiveness analysis: out of touch with clinical reality?

Maetzel A.

Arthritis Rheum. 2005 Feb 15;53(1):3-4. No abstract available.

22.

[The role of utilities in economic evaluations of healthcare interventions-an introduction].

Maetzel A.

Z Rheumatol. 2004 Oct;63(5):380-4. Review. German.

PMID:
15517298
24.

Use of mainstream nonpharmacologic treatment by patients with arthritis.

Li LC, Maetzel A, Pencharz JN, Maguire L, Bombardier C; Community Hypertension and Arthritis Project (CHAP) Team.

Arthritis Rheum. 2004 Apr 15;51(2):203-9.

25.

The economic burden associated with osteoarthritis, rheumatoid arthritis, and hypertension: a comparative study.

Maetzel A, Li LC, Pencharz J, Tomlinson G, Bombardier C; Community Hypertension and Arthritis Project Study Team.

Ann Rheum Dis. 2004 Apr;63(4):395-401.

26.
27.

Long-term antibiotic cost savings from a comprehensive intervention program in a medical department of a university-affiliated teaching hospital.

Rüttimann S, Keck B, Hartmeier C, Maetzel A, Bucher HC.

Clin Infect Dis. 2004 Feb 1;38(3):348-56. Epub 2004 Jan 13.

PMID:
14727204
28.

Towards a reference case for use in future economic evaluations of interventions in osteoarthritis.

Drummond M, Maetzel A, Gabriel S, March L.

J Rheumatol Suppl. 2003 Dec;68:26-30. Review. No abstract available.

PMID:
14712619
29.
31.

Economic evaluation of orlistat in overweight and obese patients with type 2 diabetes mellitus.

Maetzel A, Ruof J, Covington M, Wolf A.

Pharmacoeconomics. 2003;21(7):501-12.

PMID:
12696990
32.

Economic evaluation of programs or interventions in the management of rheumatoid arthritis: defining a consensus-based reference case.

Maetzel A, Tugwell P, Boers M, Guillemin F, Coyle D, Drummond M, Wong JB, Gabriel SE; OMERACT 6 Economics Research Group.

J Rheumatol. 2003 Apr;30(4):891-6.

PMID:
12672224
33.

OMERACT 6 Economics Working Group report: a proposal for a reference case for economic evaluation in rheumatoid arthritis.

Gabriel S, Drummond M, Maetzel A, Boers M, Coyle D, Welch V, Tugwell P; Patient Perspective Group.

J Rheumatol. 2003 Apr;30(4):886-90. Review.

PMID:
12672223
34.
35.

The challenges of estimating the national costs of osteoarthritis: are we making progress?

Maetzel A.

J Rheumatol. 2002 Sep;29(9):1811-3. No abstract available.

PMID:
12233870
36.

The economic burden of low back pain: a review of studies published between 1996 and 2001.

Maetzel A, Li L.

Best Pract Res Clin Rheumatol. 2002 Jan;16(1):23-30. Review.

PMID:
11987929
37.
38.

OMERACT 5 Economics Working Group: summary, recommendations, and research agenda.

Gabriel S, Drummond M, Suarez-Almazor ME, Ruff B, Guillemin F, Bombardier C, Boers M, Maetzel A, Ruof J, Cranney A, Marentette M, Tugwell P.

J Rheumatol. 2001 Mar;28(3):670-3. Review. No abstract available.

PMID:
11296980
39.

Cost assessment instrument in rheumatology: evaluation of applied instrument characteristics.

Ruof J, Merkesdal S, Huelsemann JL, Schoeffski O, Maetzel A, Mau W, Zeidler H.

J Rheumatol. 2001 Mar;28(3):662-5. Review.

PMID:
11296978
40.

Development of a matrix of cost domains in economic evaluation of rheumatoid arthritis.

Merkesdal S, Ruof J, Huelsemann JL, Schoeffski O, Maetzel A, Mau W, Zeidler H.

J Rheumatol. 2001 Mar;28(3):657-61. Review.

PMID:
11296977
41.

Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs.

Maetzel A, Wong A, Strand V, Tugwell P, Wells G, Bombardier C.

Rheumatology (Oxford). 2000 Sep;39(9):975-81.

PMID:
10986302
42.

Use of grade membership analysis to profile the practice styles of individual physicians in the management of acute low back pain.

Maetzel A, Johnson SH, Woodbury M, Bombardier C.

J Clin Epidemiol. 2000 Feb;53(2):195-205.

PMID:
10729692
44.

Pharmacoeconomic evaluation of new treatments: efficacy versus effectiveness studies?

Bombardier C, Maetzel A.

Ann Rheum Dis. 1999 Nov;58 Suppl 1:I82-5. Review.

45.

Give observational studies a chance: better observational studies make better economic evaluations.

Maetzel A, Bombardier C.

J Rheumatol. 1999 Nov;26(11):2298-9. No abstract available.

PMID:
10555880
47.

How Canadian and US rheumatologists treat moderate or aggressive rheumatoid arthritis: a survey.

Maetzel A, Bombardier C, Strand V, Tugwell P, Wells G.

J Rheumatol. 1998 Dec;25(12):2331-8.

PMID:
9858426
48.

A review of cost-effectiveness analyses in rheumatology and related disciplines.

Maetzel A, Ferraz MB, Bombardier C.

Curr Opin Rheumatol. 1998 Mar;10(2):136-40. Review.

PMID:
9567209
49.
50.

A summary of economic evaluations published in the field of rheumatology and related disciplines.

Ferraz MB, Maetzel A, Bombardier C.

Arthritis Rheum. 1997 Sep;40(9):1587-93.

PMID:
9324012

Supplemental Content

Loading ...
Support Center